Validation of the Fluid Responsiveness Index in Critically Ill Patients

NCT ID: NCT00894309

Last Updated: 2009-05-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Fluid therapy is an important part of the management of patients with hemodynamic instability in the intensive care unit. By increasing cardiac preload, it aims at elevating cardiac output (CO) and thus restoring hemodynamic conditions in patients who are preload responsive. By contrast, volume administration can be deleterious in terms of pulmonary edema formation or other manifestations or fluid overload, especially in patients who are not preload responsive. Functional dynamic parameters that use heart-lung interactions, such as pulse pressure variation (PPV) and stroke volume variation (SVV) are considered accurate predictors of preload responsiveness in patients receiving fully controlled mechanical ventilation.

However, in cases of spontaneous breathing activity where heart-lung interaction indices fail to predict fluid responsiveness, one needs parameters able to reliably predict the hemodynamic response of fluid administration.

A new index that could indicate fluid responsiveness, so-called the fluid responsiveness index (FRI), has been elaborated. The advantage is that it could be used in patients who are not in control mechanical ventilation as well as in patients who are fully adapted to mechanical ventilation.

The FRI is based upon the analysis of continuous arterial and continuous central venous pressure. The FRI is determined by the relation of cardiac and respiratory activity; both are evaluated by means of power spectrum analysis of the pressures recorded.

The aim of this study is to test the value of the FRI to predict the hemodynamic response to fluid infusion in patients with hemodynamic instability not receiving fully controlled mechanical ventilation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Shock Critically Ill

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Hospitalization in an intensive care unit
* Presence of an acute circulatory failure as defined by the presence of at least one clinical sign of inadequate global perfusion
* Decision by the attending physician to give fluids will not be taken upon criteria predefined by the study protocol but considers:

* systolic arterial pressure \< 90 mmHg (or fall of systolic arterial pressure of more than 50 mmHg in known hypertensive patients)
* urinary flow \< 0.5 ml/kg/hr than two hours
* tachycardia ≥ 100 beats/min
* delayed capillary refill
* mottled skin
* high lactate
* CO (Cardiac Output) that is not considered adequate and
* low GEDV (Global EndDiastolic Volume)
* Monitoring by a PiCCO2™ device (Pulsion Medical Systems, Munich, Germany) already in place as part of the routine hemodynamic monitoring

Exclusion Criteria

* Clinical evidence of pulmonary edema, hypervolemia or ELWI \> 10 ml/kg
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bicetre Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Medical Intensive Care Unit - Bicêtre Hospital

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Xavier Monnet, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Medical Intensive Care Unit - Bicêtre Hospital

Azriel Perel, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Anesthesiology and Intensive Care Sheba Medical Centre Tel Aviv

Jean-Louis Teboul, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Medical Intensive Care Unit - Bicêtre Hospital

Daniel Reuter, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Universitätsklinik Eppendorf, Hamburg

Wolfgang Huber, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

II. Med. Klinik, Station 2/11, Munich

Fernando Suarez Sipmann, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Unidad de cuidados intensivos, Fundacion Jimenez Diaz, Madrid

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical Intensive Care Unit

Le Kremlin-Bicêtre, , France

Site Status

Universitätsklinik Eppendorf

Hamburg, , Germany

Site Status

Klinikum Rechts der Isar

Munich, , Germany

Site Status

Department of Anesthesiology and Intensive Care Sheba Medical Centre

Tel Aviv, , Israel

Site Status

Unidad de cuidados intensivos, Fundacion Jimenez Diaz

Madrid, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France Germany Israel Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jean-Louis Teboul, MD, PhD

Role: CONTACT

+33145213547

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Xavier Monnet, MD, PhD

Role: primary

Daniel Reuter, MD, PhD

Role: primary

Wolfgang Huber, MD, PhD

Role: primary

Azriel Perel, MD, PhD

Role: primary

+972526667200

Fernando Suarez Sipmann, MD, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FRI-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.